Sengenics said this week that it will launch a cancer biomarker discovery and clinical trial immunoresponse monitoring service based on Oxford Gene Technology's functional protein array platform.
Sengenics, based in Kuala Lumpur, Malaysia, said that it will launch the service in the second quarter from a new protein array facility that has been custom built to run the OGT arrays.
Sengenics had already been offering protein array-based biomarker discovery services through OGT for a number of years. A company spokesperson said that Sengenics has built a new facility that is set to open in April and designed to run the protein array technology. "This will be the first facility in the world outside Oxford that is capable of running this platform," the spokesperson said.
In a statement, John Anson, executive vice president of R&D at OGT, noted that "enabling Sengenics, our strategic partner in Asia, to provide biomarker discovery services based on our proprietary protein array platform in their own facility" would help OGT better serve the Asian market.